Recurrent/metastatic/refractory cervical cancer
Conditions
Interventions
Case series:None
Sponsors
the First Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1.Cervical malignancy confirmed by pathology in our hospital; 2.Have received at least first-line or above platinum-containing standard chemotherapy; 3.After disease recurrence and metastasis were confirmed by pathology in our hospital or residual and persistent lesions were confirmed by imaging, "PD-1 inhibitor combined with paclitaxel-platinum" comprehensive treatment regimen was applied for at least 4 cycles; 4.Complete imaging data before and after medication: there was at least one measurable lesion according to RECIST 1.1 criteria, that is, the long diameter of non-lymph node lesion was >= 10 mm according to CT cross-sectional images or MRI, or the short diameter of lymph node lesion was >= 15 mm.
Exclusion criteria
Exclusion criteria: 1.Have received previous immunotherapy; 2.Other anti-tumor therapies (including chemotherapy, radiotherapy, and molecular targeted therapy) were received within 4 weeks prior to the start of treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate;Disease control rate;Progression-free survival;Toxic side effects; | — |
Countries
China
Contacts
Public ContactRen Fang
the First Affiliated Hospital of Zhengzhou University
Outcome results
None listed